Biotechnology
Compare Stocks
5 / 10Stock Comparison
JAGX vs PRGO vs MCK vs CAH vs HSIC
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Medical - Distribution
Medical - Distribution
Medical - Distribution
JAGX vs PRGO vs MCK vs CAH vs HSIC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Medical - Distribution | Medical - Distribution | Medical - Distribution |
| Market Cap | $199K | $1.61B | $92.15B | $43.59B | $8.09B |
| Revenue (TTM) | $12M | $4.18B | $403.43B | $250.55B | $13.18B |
| Net Income (TTM) | $-54M | $-1.82B | $4.76B | $1.56B | $398M |
| Gross Margin | 67.2% | 34.2% | 3.6% | 3.7% | 29.1% |
| Operating Margin | -398.8% | -4.1% | 1.5% | 0.9% | 5.8% |
| Forward P/E | — | 5.6x | 19.3x | 17.9x | 13.3x |
| Total Debt | $44M | $3.97B | $7.39B | $9.35B | $3.69B |
| Cash & Equiv. | $968K | $532M | $5.69B | $3.87B | $156M |
JAGX vs PRGO vs MCK vs CAH vs HSIC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 100 | 0.0 | -100.0% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| McKesson Corporation (MCK) | 100 | 474.1 | +374.1% |
| Cardinal Health, In… (CAH) | 100 | 338.7 | +238.7% |
| Henry Schein, Inc. (HSIC) | 100 | 116.1 | +16.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JAGX vs PRGO vs MCK vs CAH vs HSIC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, JAGX doesn't own a clear edge in any measured category.
PRGO has the current edge in this matchup, primarily because of its strength in defensive.
- Beta 1.18, yield 9.8%, current ratio 2.76x
- Lower P/E (5.6x vs 13.3x)
- 9.8% yield, 10-year raise streak, vs CAH's 1.1%, (2 stocks pay no dividend)
MCK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs CAH's 160.8%
- PEG 0.49 vs HSIC's 4.21
- 16.2% revenue growth vs PRGO's -2.8%
CAH ranks third and is worth considering specifically for income & stability.
- Dividend streak 20 yrs, beta 0.03, yield 1.1%
- Beta 0.03 vs JAGX's 2.72
- +22.0% vs JAGX's -99.2%
HSIC is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.73, Low D/E 76.9%, current ratio 1.38x
- 3.0% margin vs JAGX's -465.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs PRGO's -2.8% | |
| Value | Lower P/E (5.6x vs 13.3x) | |
| Quality / Margins | 3.0% margin vs JAGX's -465.4% | |
| Stability / Safety | Beta 0.03 vs JAGX's 2.72 | |
| Dividends | 9.8% yield, 10-year raise streak, vs CAH's 1.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +22.0% vs JAGX's -99.2% | |
| Efficiency (ROA) | 5.7% ROA vs JAGX's -114.3%, ROIC 5.4% vs -116.8% |
JAGX vs PRGO vs MCK vs CAH vs HSIC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
JAGX vs PRGO vs MCK vs CAH vs HSIC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CAH leads in 2 of 6 categories
HSIC leads 1 • PRGO leads 1 • MCK leads 1 • JAGX leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HSIC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 35047.3x JAGX's $12M. HSIC is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to JAGX's -4.7%. On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $12M | $4.2B | $403.4B | $250.5B | $13.2B |
| EBITDAEarnings before interest/tax | -$54M | $58M | $6.8B | $3.2B | $1.1B |
| Net IncomeAfter-tax profit | -$54M | -$1.8B | $4.8B | $1.6B | $398M |
| Free Cash FlowCash after capex | -$24M | $108M | $6.0B | $4.4B | $561M |
| Gross MarginGross profit ÷ Revenue | +67.2% | +34.2% | +3.6% | +3.7% | +29.1% |
| Operating MarginEBIT ÷ Revenue | -4.0% | -4.1% | +1.5% | +0.9% | +5.8% |
| Net MarginNet income ÷ Revenue | -4.7% | -43.5% | +1.2% | +0.6% | +3.0% |
| FCF MarginFCF ÷ Revenue | -2.1% | +2.6% | +1.5% | +1.8% | +4.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.8% | -7.2% | +6.0% | +11.0% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +90.1% | -56.4% | +37.0% | -19.5% | +14.9% |
Valuation Metrics
PRGO leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 26% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $198,587 | $1.6B | $92.1B | $43.6B | $8.1B |
| Enterprise ValueMkt cap + debt − cash | $43M | $5.1B | $93.8B | $49.1B | $11.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -1.14x | 29.25x | 28.72x | 21.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.56x | 19.28x | 17.94x | 13.26x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.75x | — | 6.84x |
| EV / EBITDAEnterprise value multiple | — | 7.42x | 18.74x | 16.01x | 10.87x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 0.38x | 0.26x | 0.20x | 0.61x |
| Price / BookPrice ÷ Book value/share | — | 0.55x | — | — | 1.79x |
| Price / FCFMarket cap ÷ FCF | 0.03x | 11.12x | 17.63x | 23.56x | 14.12x |
Profitability & Efficiency
MCK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-51 for PRGO. HSIC carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs JAGX's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -50.7% | +3.0% | — | +8.2% |
| ROA (TTM)Return on assets | -114.3% | -19.8% | +5.7% | +2.8% | +3.6% |
| ROICReturn on invested capital | -116.8% | +3.7% | +5.4% | +33.8% | +7.1% |
| ROCEReturn on capital employed | -2.9% | +4.3% | +30.5% | +19.2% | +9.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 6 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 1.35x | — | — | 0.77x |
| Net DebtTotal debt minus cash | $43M | $3.4B | $1.7B | $5.5B | $3.5B |
| Cash & Equiv.Liquid assets | $968,000 | $532M | $5.7B | $3.9B | $156M |
| Total DebtShort + long-term debt | $44M | $4.0B | $7.4B | $9.3B | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | -565.60x | -7.20x | 33.79x | 6.38x | 4.59x |
Total Returns (Dividends Reinvested)
CAH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $0 for JAGX. Over the past 12 months, CAH leads with a +22.0% total return vs JAGX's -99.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs JAGX's -93.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -91.5% | -13.5% | -8.5% | -9.5% | -8.2% |
| 1-Year ReturnPast 12 months | -99.2% | -51.2% | +4.6% | +22.0% | +5.9% |
| 3-Year ReturnCumulative with dividends | -100.0% | -58.1% | +106.4% | +127.3% | -11.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -60.1% | +286.9% | +235.7% | -12.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | -77.7% | +348.1% | +160.8% | +5.3% |
| CAGR (3Y)Annualised 3-year return | -93.8% | -25.2% | +27.3% | +31.5% | -4.0% |
Risk & Volatility
CAH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than JAGX's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAH currently trades 79.3% from its 52-week high vs JAGX's 0.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.72x | 1.18x | 0.04x | 0.03x | 0.73x |
| 52-Week HighHighest price in past year | $395.85 | $28.44 | $999.00 | $233.60 | $89.29 |
| 52-Week LowLowest price in past year | $0.71 | $9.23 | $637.00 | $137.75 | $61.95 |
| % of 52W HighCurrent price vs 52-week peak | +0.8% | +41.2% | +75.3% | +79.3% | +79.0% |
| RSI (14)Momentum oscillator 0–100 | 16.7 | 60.9 | 16.2 | 33.2 | 39.1 |
| Avg Volume (50D)Average daily shares traded | 42K | 3.4M | 757K | 1.7M | 1.2M |
Analyst Outlook
Evenly matched — PRGO and CAH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PRGO as "Hold", MCK as "Buy", CAH as "Buy", HSIC as "Hold". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 22.6% for HSIC (target: $86). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $20.00 | $1006.50 | $249.67 | $86.43 |
| # AnalystsCovering analysts | — | 36 | 31 | 33 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% | +0.4% | +1.1% | — |
| Dividend StreakConsecutive years of raises | — | 10 | 17 | 20 | 1 |
| Dividend / ShareAnnual DPS | — | $1.15 | $2.69 | $2.04 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% | +3.4% | +1.8% | +10.5% |
CAH leads in 2 of 6 categories (Total Returns, Risk & Volatility). HSIC leads in 1 (Income & Cash Flow). 1 tied.
JAGX vs PRGO vs MCK vs CAH vs HSIC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is JAGX or PRGO or MCK or CAH or HSIC a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — JAGX or PRGO or MCK or CAH or HSIC?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus McKesson Corporation at 29. 2x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Henry Schein, Inc. 's 4. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — JAGX or PRGO or MCK or CAH or HSIC?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -100. 0% for Jaguar Health, Inc. (JAGX). Over 10 years, the gap is even starker: MCK returned +348. 1% versus JAGX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — JAGX or PRGO or MCK or CAH or HSIC?
By beta (market sensitivity over 5 years), Cardinal Health, Inc.
(CAH) is the lower-risk stock at 0. 03β versus Jaguar Health, Inc. 's 2. 72β — meaning JAGX is approximately 7911% more volatile than CAH relative to the S&P 500. On balance sheet safety, Henry Schein, Inc. (HSIC) carries a lower debt/equity ratio of 77% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — JAGX or PRGO or MCK or CAH or HSIC?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — JAGX or PRGO or MCK or CAH or HSIC?
Henry Schein, Inc.
(HSIC) is the more profitable company, earning 3. 0% net margin versus -465. 4% for Jaguar Health, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -398. 8% for JAGX. At the gross margin level — before operating expenses — JAGX leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is JAGX or PRGO or MCK or CAH or HSIC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — JAGX or PRGO or MCK or CAH or HSIC?
In this comparison, PRGO (9.
8% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. JAGX, HSIC do not pay a meaningful dividend and should not be held primarily for income.
09Is JAGX or PRGO or MCK or CAH or HSIC better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Jaguar Health, Inc. (JAGX) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +160. 8%, JAGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between JAGX and PRGO and MCK and CAH and HSIC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: JAGX is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; HSIC is a small-cap quality compounder stock. PRGO, CAH pay a dividend while JAGX, MCK, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.